No Impact of COVID-19 Pandemic on Early Mortality for Thyroid Cancer in the US. Comment on Lee et al. Impact of the COVID-19 Pandemic on Thyroid Cancer Surgery. Curr. Oncol. 2024, 31, 3579–3590

The results of our analysis provide additional insights into the impact of the COVID-19 pandemic on thyroid cancer outcomes and complement the results already presented by Lee et al. Consistent with their finding that patients with thyroid cancer had similar treatment times before (i.e., in 2019) and during the early phase of the pandemic (i.e., in 2020), we also failed to find a significant difference in the age-adjusted mortality rate between 2018 and 2022. This evidence is consistent with other previous reports, such as that of Kathuria-Prakash et al., who found that initial disease burden and extent, as well as therapy and its response, showed no significant association with the severity of COVID-19, or the report of Sahin et al., which showed that COVID-19 disease does not cause an enhanced risk of death in patients with a history of thyroid cancer.